Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Voriconazole in Invasive Fungal Infections
NCT00001810Phase 3Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 1999
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of voriconazole in invasive fungal infection (IFI), sponsored by National Cancer Institute. Primary endpoints: Clinical Response, Radiological Response and 1 more. Started Apr 1999; status: completed.
02
Drugs
voriconazole
03
Conditions
invasive fungal infection (IFI)
Beyond the preview
Go deeper on NCT00001810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001810.